Histone deacetylase inhibitors and hydroxyurea modulate the cell cycle and cooperatively induce apoptosis

被引:74
作者
Kraemer, O. H. [1 ]
Knauer, S. K. [2 ]
Zimmermann, D. [3 ]
Stauber, R. H. [2 ]
Heinzel, T. [1 ]
机构
[1] Univ Jena, Inst Biochem & Biophys, Jena, Germany
[2] Univ Hosp Mainz, Mainz, Germany
[3] Inst Biomed Res, Frankfurt, Germany
关键词
VPA; HDAC inhibitor; hydroxyurea; caspase-3; CDKI p21/p27; chemotherapy resistance;
D O I
10.1038/sj.onc.1210677
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Therapy resistance represents a major problem for disease management in oncology. Histone deacetylase inhibitors (HDACi) have been shown to modulate the cell cycle, to induce apoptosis and to sensitize cancer cells for other chemotherapeutics. Our study shows that the HDACi valproic acid (VPA) and the ribonucleotide reductase inhibitor hydroxyurea (HU) potentiate the pro-apoptotic effects of each other towards several cancer cell lines. This correlates with the HU-induced degradation of the cyclin-dependent kinase inhibitors (CDKI) p21 and p27, mediated by the proteasome or caspase-3. Moreover, we found that caspase-3 activation is required for VPA induced apoptosis. Remarkably, p21 and p27 can confer resistance against VPA and HU. Both CDKI interact with caspase-3 and compete with other caspase-3 substrates. Hence, p21 and p27 may contribute to chemotherapy resistance as apoptosis inhibitors. Since the biological effects of VPA and HU could be achieved at concentrations used in current treatment protocols, the combined application of these compounds might be considered as a potential strategy for cancer treatment.
引用
收藏
页码:732 / 740
页数:9
相关论文
共 37 条
[1]   Are p27 and p21 Cytoplasmic Oncoproteins? [J].
Blagosklonny, Mikhail V. .
CELL CYCLE, 2002, 1 (06) :391-393
[2]   Histone deacetylase inhibitors and malignant melanoma [J].
Boyle, GM ;
Martyn, AC ;
Parsons, PG .
PIGMENT CELL RESEARCH, 2005, 18 (03) :160-166
[3]   Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemia [J].
Bug, G ;
Ritter, M ;
Wassmann, B ;
Schoch, C ;
Heinzel, T ;
Schwarz, K ;
Romanski, A ;
Kramer, OH ;
Kampfmann, M ;
Hoelzer, D ;
Neubauer, A ;
Ruthardt, M ;
Ottmann, OG .
CANCER, 2005, 104 (12) :2717-2725
[4]   Inducible P27Kip1 expression inhibits proliferation of K562 cells and protects against apoptosis induction by proteasome inhibitors [J].
Drexler, HCA ;
Pebler, S .
CELL DEATH AND DIFFERENTIATION, 2003, 10 (03) :290-301
[5]   p27Kip1 induces drug resistance by preventing apoptosis upstream of cytochrome c release and procaspase-3 activation in leukemic cells [J].
Eymin, B ;
Haugg, M ;
Droin, N ;
Sordet, O ;
Dimanche-Boitrel, MT ;
Solary, E .
ONCOGENE, 1999, 18 (07) :1411-1418
[6]   Inhibitors of histone deacetylase arrest cell cycle and induce apoptosis in cervical carcinoma cells circumventing human papillomavirus oncogene expression [J].
Finzer, P ;
Kuntzen, C ;
Soto, U ;
Zur Hausen, H ;
Rösl, F .
ONCOGENE, 2001, 20 (35) :4768-4776
[7]   Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells [J].
Göttlicher, M ;
Minucci, S ;
Zhu, P ;
Krämer, OH ;
Schimpf, A ;
Giavara, S ;
Sleeman, JP ;
Lo Coco, F ;
Nervi, C ;
Pelicci, PG ;
Heinzel, T .
EMBO JOURNAL, 2001, 20 (24) :6969-6978
[8]   The hallmarks of cancer [J].
Hanahan, D ;
Weinberg, RA .
CELL, 2000, 100 (01) :57-70
[10]   Caspase-3 is required for DNA fragmentation and morphological changes associated with apoptosis [J].
Jänicke, RU ;
Sprengart, ML ;
Wati, MR ;
Porter, AG .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (16) :9357-9360